In vitro and mouse model studies show that disrupting SAM production via CRISPR-Cas9-mediated deletion of the MAT2A gene reduces T cell dysfunction and inhibits HCC growth, suggesting that targeting methionine metabolism could enhance anti-tumor immunity in HCC [76]. The gene discussed is MAT2A; the disease is hepatocellular carcinoma.